OrbiMed’s Crinetics Pharmaceuticals CRNX Stock Holding History

OrbiMed’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.4M	Hold	999,000	–	–	0.69%	43
2026 Q1	$36.3M	Hold	999,000	–	–	0.72%	41
2025 Q4	$46.5M	Sell	999,000 -100,000	-9%	-$4.45M	0.95%	31
2025 Q3	$45.8M	Sell	1,099,000 -50,000	-4%	-$1.6M	1.08%	32
2025 Q2	$33M	Buy	1,149,000 +150,000	+15%	+$4.63M	0.83%	30
2025 Q1	$33.5M	Hold	999,000	–	–	0.8%	35
2024 Q4	$51.1M	Sell	999,000 -51,055	-5%	-$2.86M	1.05%	28
2024 Q3	$53.7M	Sell	1,050,055 -230,745	-18%	-$11.9M	0.98%	30
2024 Q2	$57.4M	Sell	1,280,800 -104,200	-8%	-$4.81M	1.13%	27
2024 Q1	$64.8M	Sell	1,385,000 -282,360	-17%	-$11M	1.19%	27
2023 Q4	$59.3M	Sell	1,667,360 -1,228,714	-42%	-$37.7M	1.18%	31
2023 Q3	$86.1M	Sell	2,896,074 -1,054,722	-27%	-$21.7M	1.83%	14
2023 Q2	$71.2M	Hold	3,950,796	–	–	1.29%	28
2023 Q1	$63.4M	Buy	3,950,796 +753,920	+24%	+$14M	1.25%	24
2022 Q4	$58.5M	Hold	3,196,876	–	–	1.12%	33
2022 Q3	$62.8M	Hold	3,196,876	–	–	1.17%	30
2022 Q2	$59.6M	Hold	3,196,876	–	–	1.08%	30
2022 Q1	$70.2M	Hold	3,196,876	–	–	1.14%	31
2021 Q4	$90.8M	Buy	3,196,876 +200,000	+7%	+$4.93M	1.17%	31
2021 Q3	$63.1M	Hold	2,996,876	–	–	0.69%	46
2021 Q2	$56.5M	Buy	2,996,876 +243,309	+9%	+$4.28M	0.57%	51
2021 Q1	$42.1M	Hold	2,753,567	–	–	0.39%	69
2020 Q4	$38.9M	Hold	2,753,567	–	–	0.34%	70
2020 Q3	$43.1M	Hold	2,753,567	–	–	0.54%	56
2020 Q2	$48.2M	Buy	2,753,567 +714,285	+35%	+$12.2M	0.68%	46
2020 Q1	$30M	Hold	2,039,282	–	–	0.5%	54
2019 Q4	$51.2M	Hold	2,039,282	–	–	0.73%	44
2019 Q3	$30.7M	Hold	2,039,282	–	–	0.58%	49
2019 Q2	$51M	Buy	2,039,282 +125,000	+7%	+$3.1M	0.79%	39
2019 Q1	$43.6M	Hold	1,914,282	–	–	0.67%	43
2018 Q4	$57.4M	Hold	1,914,282	–	–	1.06%	30
2018 Q3	$54.8M	Buy	+1,914,282	New	+$56.8M	0.66%	44

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's CRNX Position: Q2 2026 in Review

OrbiMed held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 999,000 shares worth $37.4M. The position accounts for 0.69% of the portfolio, ranked #43.

OrbiMed first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $90.8M in Q4 2021. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

OrbiMed held 999,000 shares of Crinetics Pharmaceuticals worth $37.4M as of Q2 2026.
OrbiMed left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up 0.69% of OrbiMed's portfolio in Q2 2026, its #43 holding.
OrbiMed first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
OrbiMed's Crinetics Pharmaceuticals position peaked at $90.8M in Q4 2021.
266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.